ELTP (Elite Pharmaceuticals) LT-Debt-to-Total-Asset: 0.04 (As of Dec. 2025)

What is Elite Pharmaceuticals LT-Debt-to-Total-Asset?

Elite Pharmaceuticals ELTP +2.62% 44 LT-Debt-to-Total-Asset is 0.04 as of Dec. 2025. GuruFocus rates ELTP with a GF Score™ of 44/100 and a GF Value™ of $0.57 (Possible Value Trap). The stock has 1 warning sign investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Elite Pharmaceuticals's long-term debt to total assests ratio for the quarter that ended in Dec. 2025 was 0.04.

Elite Pharmaceuticals's long-term debt to total assets ratio declined from Dec. 2024 (0.07) to Dec. 2025 (0.04). It may suggest that Elite Pharmaceuticals is progressively becoming less dependent on debt to grow their business.

Elite Pharmaceuticals (OTCPK:ELTP) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Elite Pharmaceuticals LT-Debt-to-Total-Asset Related Terms

Elite Pharmaceuticals LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Elite Pharmaceuticals's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Elite Pharmaceuticals LT-Debt-to-Total-Asset Chart

Elite Pharmaceuticals Annual Data

Trend

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Mar25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.07

0.06

0.09

0.08

0.06

Elite Pharmaceuticals Quarterly Data
	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.07	0.06	0.05	0.04	0.04

44GF Score

Elite Pharmaceuticals Inc ELTP

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Elite Pharmaceuticals LT-Debt-to-Total-Asset Calculation

Elite Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Mar. 2025 is calculated as

LT Debt to Total Assets (A: Mar. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Mar. 2025 )	/	Total Assets (A: Mar. 2025 )
	=	5.833	/	96.387
	=	0.06

Elite Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (Q: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2025 )	/	Total Assets (Q: Dec. 2025 )
	=	4.94	/	126.413
	=	0.04

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.04 mean?

Elite Pharmaceuticals (ELTP) has a LT-Debt-to-Total-Asset of 0.04 as of Dec. 2025. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Elite Pharmaceuticals and its competitors.

Is Elite Pharmaceuticals' LT-Debt-to-Total-Asset too high?

Elite Pharmaceuticals' current LT-Debt-to-Total-Asset is 0.04. Overall, Elite Pharmaceuticals has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.

How does Elite Pharmaceuticals' LT-Debt-to-Total-Asset compare to SIGA and ORGO?

Elite Pharmaceuticals' LT-Debt-to-Total-Asset of 0.04 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Drug Manufacturers company?

A good LT-Debt-to-Total-Asset depends on the Drug Manufacturers industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Elite Pharmaceuticals and its competitors. Elite Pharmaceuticals's current LT-Debt-to-Total-Asset is 0.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Elite Pharmaceuticals stock overvalued right now?

Based on GuruFocus' analysis, Elite Pharmaceuticals (ELTP) is currently considered Possible Value Trap. The stock's GF Value™ is $0.57, compared to a current price of $0.40 — trading 30.7% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.04. Elite Pharmaceuticals' overall GF Score™ is 44/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Elite Pharmaceuticals (ELTP), the current LT-Debt-to-Total-Asset is 0.04 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Elite Pharmaceuticals (ELTP) Overvalued in 2026?

Based on GuruFocus' analysis, Elite Pharmaceuticals stock appears to be undervalued. The current stock price of $0.40 is trading 30.7% below its estimated GF Value™ of $0.57. GuruFocus considers Elite Pharmaceuticals to be Possible Value Trap.

Key valuation signals for ELTP:

LT-Debt-to-Total-Asset: 0.04
GF Value™: $0.57 vs. price of $0.40 (30.7% below fair value)
GF Score™: 44/100 with 1 warning sign

No single metric tells the full story. See the ELTP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Elite Pharmaceuticals Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies SIGA ORGO EOLS TKNO AKBA EBS AQST NIKA ANIK LFCR XTER:MRK TSE:4502 XSWX:GALD SHSE:600276 NSE:SUNPHARMA XTAE:TEVA LSE:HLN XSWX:SDZ ZTS HKSE:03692

Address 165 Ludlow Avenue, Northvale, NJ, USA, 07647

Website https://www.elitepharma.com

Elite Pharmaceuticals Inc is a pharmaceutical company. It is principally engaged in the development and manufacture of oral, controlled-release products, using proprietary know-how and technology. The company's operating segment includes Abbreviated New Drug Applications (ANDA) and New Drug Applications (NDA). It generates maximum revenue from the ANDA segment. The company focuses on developing pain management products; manufacturing a line of generic pharmaceutical products with approved Abbreviated New Drug Applications; developing additional generic pharmaceutical products; development of other products in its pipeline including the products with its partners; and commercialization of new products.

44GF Score

Get the complete analysis for ELTP

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.40

Price

$0.57

GF Value

View ELTP Analysis

See LT-Debt-to-Total-Asset data for all stocks →